{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.57","upperLimit":"21.49","value":"17.15"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"}],"units":"Participants"}],"description":"Median time to progression or death assessed by biochemistry, radiology and immunology tests will be reported. Progression is evaluated in this study using the International Myeloma Working Group Uniform Response Criteria (IMWG-URC) with any one or more of the following:\n\n1. Increase of ≥ 25% from lowest response value in: Serum M-component and/or Urine M-component and/or Only in patients without measurable serum and urine M-protein levels; the difference between involved and uninvolved FLC levels or Bone marrow plasma cell percentages.\n2. Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas\n3. Development of hypercalcemia (corrected serum calcium \\> 11.5 mg/dL (0.115 g/L) or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder.","dispersionType":"95% Confidence Interval","groups":[{"description":"20 mg/m2 day 1 of first cycle then escalated to 70 mg/m2 for all subsequent doses) given on days 1, 8, and 15 of a 28 day cycle plus weekly oral dexamethasone (\\< 70 years, 40 mg; ≥ 70 years 20mg) and cyclophosphamide 300 mg/m2 capped at 500 mg\n\nCarfilzomib\n\nCyclophosphamide\n\nDexamethasone","id":"OG000","title":"Carfilzomib Plus Cyclophosphamide Plus Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"All treated patients were included in the analysis","reportingStatus":"POSTED","timeFrame":"3 years","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}